Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $53
Tandem Diabetes Care Is Maintained at Overweight by Barclays
Tandem Diabetes Care Price Target Cut to $53.00/Share From $60.00 by Barclays
Tandem Diabetes Care Analyst Ratings
Bernstein Downgrades Tandem Diabetes Care(TNDM.US) to Hold Rating, Cuts Target Price to $25
Bernstein Downgrades Tandem Diabetes Care (TNDM) to a Hold
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $35 to $75
Tandem Diabetes Care (TNDM) Receives a Buy From Barclays
RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $55
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $18 to $55
Tandem Diabetes Care Is Maintained at Neutral by Baird
Stifel Nicolaus Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)
Tandem Diabetes Care: Strong International Sales and Promising 2025 Outlook Justify Buy Rating
Tandem Diabetes Care Is Maintained at Buy by Canaccord Genuity
Tandem Diabetes Care Price Target Maintained With a $63.00/Share by Canaccord Genuity
Tandem Diabetes Care Analyst Ratings
Wells Fargo Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $55
CCORF Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $63
Bernstein Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $44
RBC Capital Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $65